KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInventory AverageInvested Capital

Astrazeneca (AZN) Equity Ratio (2016 - 2025)

Astrazeneca has reported Equity Ratio over the past 11 years, most recently at 0.43 for Q4 2025.

  • Quarterly results put Equity Ratio at 0.43 for Q4 2025, up 8.71% from a year ago — trailing twelve months through Dec 2025 was 0.43 (up 8.71% YoY), and the annual figure for FY2025 was 0.43, up 8.71%.
  • Equity Ratio for Q4 2025 was 0.43 at Astrazeneca, up from 0.39 in the prior quarter.
  • Over the last five years, Equity Ratio for AZN hit a ceiling of 377.76 in Q4 2021 and a floor of 0.38 in Q4 2022.
  • Median Equity Ratio over the past 5 years was 0.43 (2025), compared with a mean of 100.82.
  • Biggest five-year swings in Equity Ratio: crashed 99.9% in 2022 and later soared 32478.7% in 2023.
  • Astrazeneca's Equity Ratio stood at 377.76 in 2021, then tumbled by 99.9% to 0.38 in 2022, then soared by 32478.7% to 125.13 in 2023, then plummeted by 99.69% to 0.39 in 2024, then rose by 8.71% to 0.43 in 2025.
  • The last three reported values for Equity Ratio were 0.43 (Q4 2025), 0.39 (Q4 2024), and 125.13 (Q4 2023) per Business Quant data.